167 related articles for article (PubMed ID: 35908023)
1. The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Tam S; Al-Zubaidi Y; Rahman MK; Bourget K; Zhou F; Murray M
Pharmacol Rep; 2022 Oct; 74(5):998-1010. PubMed ID: 35908023
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells.
Rahman MK; Al-Zubaidi Y; Bourget K; Chen Y; Tam S; Zhou F; Murray M
J Pharm Sci; 2022 Aug; 111(8):2180-2190. PubMed ID: 35700798
[TBL] [Abstract][Full Text] [Related]
3. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
[TBL] [Abstract][Full Text] [Related]
6. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Chen YJ; Yeh MH; Yu MC; Wei YL; Chen WS; Chen JY; Shih CY; Tu CY; Chen CH; Hsia TC; Chien PH; Liu SH; Yu YL; Huang WC
Breast Cancer Res; 2013 Nov; 15(6):R108. PubMed ID: 24216290
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
Yi YW; Hong W; Kang HJ; Kim HJ; Zhao W; Wang A; Seong YS; Bae I
J Cell Mol Med; 2013 May; 17(5):648-56. PubMed ID: 23601074
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
Taurin S; Rosengren RJ
Med Oncol; 2022 Dec; 40(1):45. PubMed ID: 36494506
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Zhang QC; Jiang SJ; Zhang S; Ma XB
Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
[TBL] [Abstract][Full Text] [Related]
15. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Collins DM; Crown J; O'Donovan N; Devery A; O'Sullivan F; O'Driscoll L; Clynes M; O'Connor R
Invest New Drugs; 2010 Aug; 28(4):433-44. PubMed ID: 19499189
[TBL] [Abstract][Full Text] [Related]
17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp.
Kim JY; Kim HS; Yoon S
Anticancer Res; 2019 Jul; 39(7):3785-3793. PubMed ID: 31262905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
